6533b820fe1ef96bd12792ad
RESEARCH PRODUCT
What Is the Most Recent Evidence on the Prevention and Early Treatment of Invasive Fungal Infections in Nonneutropenic Critically Ill Patients?
Santi Maurio RaineriAntonino GiarratanoVincenzo RussottoPasquale IozzoAndrea Cortegianisubject
Antifungalmedicine.medical_specialtymedicine.drug_classFungal sepsisToxicologyCritical Care and Intensive Care Medicinelaw.invention03 medical and health sciencesHigh morbidityInvasive fungal infection0302 clinical medicineRandomized controlled triallawIntensive careMedicineAntifungal treatment030212 general & internal medicineIntensive care medicineCandida sppFungal sepsibusiness.industryCritically illPublic Health Environmental and Occupational Health030208 emergency & critical care medicineClinical PracticeAntifungal treatment; Candida spp; Fungal sepsis; Invasive fungal infectionInfectious DiseasesSystematic reviewFungal sepsisbusinessdescription
: Invasive fungal infections (IFIs) are associated with high morbidity and mortality in intensive care units. Candida species are the most important fungal pathogens and among the most frequent causes of infection in critically ill patients. Studies have evaluated the correlation between the onset of antifungal treatment and survival. However, definitive diagnosis of IFI is time-consuming in clinical practice. Antifungal prophylaxis and preemptive or empirical treatments are among therapeutic strategies to prevent or treat early fungal infections in selected patients. Recently, new evidence from randomized controlled trials and systematic reviews has been published. Moreover, new clinical practice guidelines from international communities are available. The aim of this review was to present updated evidence on this topic.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2017-09-24 | Archives of Clinical Infectious Diseases |